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ASSESSING THE CROSS-CULTURAL COMPARABILITY OF THE
CENTRE FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE
(CES-D)
Meads DM, McKenna SP, Doward LC
Galen Research, Manchester, UK
OBJECTIVES: The Centre for Epidemiologic Studies Depression
Scale (CES-D) is one of the most widely used depression ques-
tionnaires; it has been translated into many languages and is fre-
quently used in multi-national studies. This research sought to
examine whether different language versions of the CES-D were
affected by country (cultural)-related differential item func-
tioning (DIF). METHODS: CES-D data were available from
depressed patients in the UK (n = 177), US (n = 100), Germany
(n = 78) and France (n = 124). The data were pooled and applied
to the one-parameter Rasch item-response model for analysis
and to identify cross-cultural DIF. RESULTS: The UK and
German CES-D did not ﬁt the Rasch model (Chi2 p < 0.001) sug-
gesting that summation of item scores in these countries is not
justiﬁed. Four items in the UK (including 2 of the 4 positively
worded items) and 2 items in Germany misﬁtted. The US CES-
D exhibited borderline overall misﬁt to the Rasch model (Chi2
p < 0.01) with no item misﬁt and the French data ﬁtted the Rasch
model (with 1 item misﬁtting). The pooled data from the 4 coun-
tries did not ﬁt the Rasch model (Chi2 p < 0.001) and DIF was
observed in 7 items (including all of the positively worded items).
DIF between the US and UK (5 items), the US and Germany 
(5 items) and US and France (4 items) was greater than that
between UK and Germany (1 item), the UK and France (2 items)
and Germany and France (3 items). CONCLUSIONS: CES-D
data from these countries cannot be pooled justiﬁably without
ﬁrst accounting for DIF by culture. DIF appeared to be greater
between the US and Europe than within European countries. In
addition, the use of both positively and negatively worded items
in a questionnaire may introduce bias.
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MEASURING RELAPSE AFTER ADOLESCENT SUBSTANCE
ABUSE TREATMENT: A PROPORTIONAL HAZARD APPROACH
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OBJECTIVES: Cox regression is used to analyze relapse patterns
of adolescents treated for psychoactive substance use disorder
(PSUD). The objective is to evaluate the role numerous psy-
chosocial, treatment and environmental characteristics play in
the relapse process in this treatment population. It is clear that
the PSUD disease and recovery process are unique in adolescents
and that relapse and recovery need rigorous study. Relapse is the
most important treatment outcome. METHODS: Subjects are
509 adolescents discharged from an ASAM-deﬁned Level 1. A
primary inpatient treatment program from 2001–2005. Data
was collected as part of the treatment program’s annual out-
comes evaluation. The sampling frame was all who successfully
completed treatment. Response rate was 61%. Analysis of char-
acteristics of nonrespondents showed no signiﬁcant differences
compared to respondents. The survey is based on a 230-item
questionnaire. Treatment records of each adolescent completing
the questionnaire were obtained for matching treatment 
outcomes from the questionnaire to treatment and sociodemo-
graphic variables contained in treatment records. A comprehen-
sive data set was created from these two sources. Data were
analyzed using Cox proportional hazard regression. RESULTS:
Results indicate race (Whites were 59.2% less likely to relapse
than other races; blacks are 4.9 times more likely.), gender (males
1.28 times more likely), participation in support groups (partic-
ipants 23.7% less likely), school attendance (attendees 21.6%
less likely), supportive friendships (one SD change on scale cor-
responds to a 7.7% reduction in relapse risk), and cannabis
dependence (cannabis diagnosis 28.7% more likely) are signiﬁ-
cant determinants of relapse, certis paribus. CONCLUSIONS:
Several risk factors for relapse are identiﬁed that can be
addressed in primary treatment. For instance, treatment pro-
grams emphasizing friendships skills by application of social cog-
nitive theory might be considered.
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OBJECTIVE: Metabolic syndrome is the constellation of central
obesity, dyslipidemia, impaired glucose tolerance, and elevated
blood pressure (BP). We analyzed the components of metabolic
syndrome via EHR databases. METHODS: Ambulatory elec-
tronic health record data for 3,301,897 patients included demo-
graphics, vitals, labs, drugs and payment types from the GE
Centricity EMR research database. The study period was
January 1, 2003 to December 31, 2004. Patients aged 18 to 64
years with any indicator of cardio-metabolic risk were identiﬁed
by clinical (biometrics), diagnosis (ICD-9 codes) or treatment
(prescriptions) information. RESULTS: The ﬁnal study popula-
tion was 475,651 patients after patients with bariatric surgery
or body mass index (BMI) > 35 kg m2 were excluded. The total
of 266,371 (56%) patients had BP as a risk factor. A total of
162,521 (34.17%) had BMI as a risk factor. When the patients
excluded for morbid obesity were included this rose to 43.8%.
Triglycerides (TG) were identiﬁed as a risk factor in 10.74%,
high density lipoproteins (HDL) in 15.99%, impaired fasting
glucose in 8.83%, diabetes in 7.22% and metabolic syndrome
(diagnosis) in 0.12%. All risk factors, except HDL had values
for all three deﬁnitions (clinical, treatment and diagnosis) of
metabolic syndrome. Of these, out of range BMI values were pri-
marily established by the clinically-based BMI deﬁnition
(33.34%) with the diagnosis and treatment deﬁnitions identify-
ing less that 2%. Over 50% of the patients with elevated BP were
identiﬁed clinically while treatment and diagnosis-based deﬁni-
tions identiﬁed only 18% and 7% of the patients with elevated
BP, respectively. Diabetes was more similar across all three deﬁ-
nitions (range 2.37%–4.69%). CONCLUSION: Distribution of
clinical risk factors in a primary care database closely mirrors
that established by prospective national health surveys. The key
source of identiﬁcation of risk factors is clinically based biomet-
ric information. Studies on metabolic syndrome need to incor-
porate clinically based information.
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